Fosamax Osteonecrosis of the Jaw Settlement: Criteria Explained

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Exposure Concerns

This domain has historically provided broad educational resources on medical conditions and therapeutic options, establishing a trusted context for discussing pharmaceutical interventions. The focus now narrows from general health perspectives to specific occupational exposure concerns. In mass production environments, workers may encounter materials and processes involving prolonged or high-concentration contact with pharmaceutical compounds. This shift requires examining how routine handling, manufacturing, or packaging activities could lead to unintended exposure. Unlike patient consumption, occupational contact often involves repeated, chronic exposure to active ingredients or intermediates. Understanding this distinction is critical for evaluating risk in industrial settings. The following discussion addresses how exposure during mass production relates to specific health outcomes, moving from general awareness to targeted occupational considerations.

Find Out If You Qualify for Compensation →

Bridging to Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication prescribed to treat osteoporosis. A known but rare adverse effect is osteonecrosis of the jaw (ONJ), a condition involving bone death in the mandible or maxilla. Understanding the clinical presentation, mechanistic links, and settlement criteria for affected patients requires careful examination of available evidence. This section bridges the occupational exposure context to the specific drug and its associated risks.

Clinical Presentation and Diagnosis of ONJ

Osteonecrosis of the jaw is characterized by exposed, non-healing bone in the oral cavity, often occurring spontaneously or following dental procedures. The condition is generally associated with tooth extraction and/or local infection with delayed healing, as reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Fosamax Pharmacology and Reported Adverse Effects

Fosamax works by inhibiting bone resorption, which helps increase bone density in osteoporosis patients. However, this mechanism may also disrupt normal bone turnover in the jaw. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, though a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to ONJ

Research has explored how bisphosphonates affect jawbone structure. A multiscale characterization of jawbone in estrogen-deficient rats treated with alendronate found that most jawbone characteristics in ovariectomized (OVX) and treatment groups were not significantly different from those of the sham group (https://pubmed.ncbi.nlm.nih.gov/40345077/). The surface of alveolar bone surrounding teeth showed a trend of more erosion and addition of new bone tissues in the OVX rat groups compared to the sham group (https://pubmed.ncbi.nlm.nih.gov/40345077/). All tissue mineral density parameters rapidly increased up to 60 μm from the periodontal ligament surrounding teeth regardless of the treatment groups (https://pubmed.ncbi.nlm.nih.gov/40345077/). Treatments using each therapeutic agent and its combination did not substantially change those characteristics of jawbones in OVX rats, findings that are different from those of lumbar vertebrae in the same rats that showed significant bone alteration by OVX and treatments (https://pubmed.ncbi.nlm.nih.gov/40345077/). This multiscale characterization provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Adequacy of Warnings Regarding Fosamax and ONJ

The prescribing information for Fosamax includes a specific warning about osteonecrosis of the jaw. The label states that ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Settlement-Related Considerations for Affected Patients

Settlement criteria for Fosamax-related ONJ cases typically require evidence of a diagnosis of osteonecrosis of the jaw following Fosamax use, with consideration of the timeline between exposure and documented harm. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients must also demonstrate that other risk factors, such as invasive dental procedures, cancer diagnosis, or concomitant therapies, were not the primary cause. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), so longer-term users may have stronger claims. Additionally, patients who experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate may have more compelling evidence of causation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Timeline Between Exposure and Documented Harm

The timeline for ONJ development after starting Fosamax is variable, with symptoms appearing from one day to several months after initiation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For settlement purposes, documentation of the date of first Fosamax use, the date of ONJ diagnosis, and any dental procedures or infections in the interim is critical.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition involving bone death in the jaw, characterized by exposed, non-healing bone. It has been reported in patients taking bisphosphonates like Fosamax (alendronate), often occurring after dental procedures or spontaneously. The prescribing information includes a warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the settlement criteria for Fosamax-related ONJ cases?

Settlement criteria typically require a confirmed diagnosis of ONJ following Fosamax use, with documentation of the timeline between exposure and harm. Patients must show that other risk factors (e.g., dental procedures, cancer, other medications) were not the primary cause. Longer duration of Fosamax use and recurrence upon rechallenge may strengthen a claim (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.